← All trials
NCT04510493
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 23, 2020
- Primary completion
- Sep 30, 2023
- Completion date
- Sep 30, 2023
- First posted
- Aug 12, 2020
- Last posted
- Nov 4, 2020
- Enrollment
- 116
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of BaselLead sponsor
- Swiss National Science FoundationCollaborator
- University of BaselOverall official - principal investigator
- University of BaselOfficial
- NovartisCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.